| Date Filed | Type | Description |
| 09/29/2023 |
4
| Lonial Sagar (Director) has filed a Form 4 on TG THERAPEUTICS, INC.|
Txns:
| Granted 20,000 shares
@ $0 |
|
| 09/29/2023 |
4
| Hoberman Kenneth (Director) has filed a Form 4 on TG THERAPEUTICS, INC.|
Txns:
| Granted 20,000 shares
@ $0 |
|
| 08/14/2023 |
4
| WEISS MICHAEL S (CEO and President) has filed a Form 4 on TG THERAPEUTICS, INC.|
Txns:
| Bought 100,000 shares
@ $10.13, valued at
$1M
|
|
| 08/04/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 08/01/2023 |
8-K
| Quarterly results |
| 06/05/2023 |
4
| Power Sean A (CFO) has filed a Form 4 on TG THERAPEUTICS, INC.|
Txns:
| Sold 73,647 shares
@ $26.7, valued at
$2M
|
|
| 06/02/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 05/08/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
| 05/01/2023 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 05/01/2023 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 05/01/2023 |
8-K
| Quarterly results |
| 04/21/2023 |
PRE 14A
| Form PRE 14A - Other preliminary proxy statements: |
| 04/03/2023 |
SC 13G
| Darwin Global Management, Ltd. reports a 7.1% stake in TG Therapeutics, Inc. |
| 03/14/2023 |
4
| Power Sean A (CFO) has filed a Form 4 on TG THERAPEUTICS, INC.|
Txns:
| Granted 85,000 shares
@ $0 |
|
| 03/14/2023 |
4
| WEISS MICHAEL S (CEO and President) has filed a Form 4 on TG THERAPEUTICS, INC.|
Txns:
| Granted 985,000 shares
@ $0 |
|
| 03/01/2023 |
10-K
| Annual Report for the period ended December 31, 2022 |
| 02/28/2023 |
8-K
| Quarterly results |
| 02/09/2023 |
SC 13G/A
| FMR LLC reports a 4.9% stake in TG THERAPEUTICS INC |
| 02/09/2023 |
SC 13G/A
| VANGUARD GROUP INC reports a 10.7% stake in TG Therapeutics Inc. |
| 02/01/2023 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 01/06/2023 |
4
| Echelard Yann (Director) has filed a Form 4 on TG THERAPEUTICS, INC.|
Txns:
| Bought 9,000 shares
@ $10.64, valued at
$95.8k
|
|
| 01/06/2023 |
4
| Charney Laurence N (Director) has filed a Form 4 on TG THERAPEUTICS, INC.|
Txns:
| Sold 30,000 shares
@ $11.1, valued at
$333k
|
|
| 12/28/2022 |
8-K
| Quarterly results |
| 11/10/2022 |
8-K
| Quarterly results |
| 11/09/2022 |
10-Q
| Quarterly Report for the period ended September 30, 2022 |
| 10/11/2022 |
SC 13G/A
| VANGUARD GROUP INC reports a 10.2% stake in TG Therapeutics Inc. |
| 09/02/2022 |
S-3ASR
| Form S-3ASR - Automatic shelf registration statement of securities of well-known seasoned issuers: |
| 08/09/2022 |
10-Q
| Quarterly Report for the period ended June 30, 2022 |
| 08/08/2022 |
8-K
| Quarterly results |
| 07/22/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 07/22/2022 |
4
| Power Sean A (CFO) has filed a Form 4 on TG THERAPEUTICS, INC.|
Txns:
| Granted 75,000 shares
@ $0
Granted 200,000 options to buy
@ $7, valued at
$1.4M
|
|
| 07/22/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 07/22/2022 |
4
| HUME DANIEL (Director) has filed a Form 4 on TG THERAPEUTICS, INC.|
Txns:
| Granted 43,732 shares
@ $0 |
|
| 07/22/2022 |
4
| Hoberman Kenneth (Director) has filed a Form 4 on TG THERAPEUTICS, INC.|
Txns:
| Granted 43,732 shares
@ $0 |
|
|